List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Restenosis - Overview
Restenosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Restenosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Restenosis - Companies Involved in Therapeutics Development
Bristol-Myers Squibb Co
CytoTools AG
Johnson & Johnson
VasThera Research Institute
Restenosis - Drug Profiles
(connective tissue growth factor + insulin human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
apixaban - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bermekimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMW-02Ak - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMW-02Ap - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate PRDX2 for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TW-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Restenosis - Dormant Projects
Restenosis - Discontinued Products
Restenosis - Product Development Milestones
Featured News & Press Releases
Jan 03, 2013: XBiotech Receives Fast Track Designation From FDA For True Human Monoclonal Antibody Therapy Targeting Inflammatory Cytokine IL-1a For Restenosis
Nov 20, 2012: XBiotech Reports Positive Phase II Interim Analysis Results Of MABp1 In Vascular Disease
Aug 18, 2011: XBiotech Announces Initiation Of Restenosis Clinical Trial In All Five US Sites
Dec 22, 2010: XBiotech Files IND For CV-18C3 Monoclonal Antibody Therapy To Treat Peripheral Vascular Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Restenosis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Restenosis - Pipeline by Bristol-Myers Squibb Co, H1 2020
Restenosis - Pipeline by CytoTools AG, H1 2020
Restenosis - Pipeline by Johnson & Johnson, H1 2020
Restenosis - Pipeline by VasThera Research Institute, H1 2020
Restenosis - Dormant Projects, H1 2020
Restenosis - Dormant Projects, H1 2020 (Contd..1), H1 2020
Restenosis - Discontinued Products, H1 2020

List of Figures
Number of Products under Development for Restenosis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

Companies Mentioned
• Bristol-Myers Squibb Co
• CytoTools AG
• Johnson & Johnson
• VasThera Research Institute